↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant(2008).„Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”.Annual Reports in Computational Chemistry4: 217-241.DOI:10.1016/S1574-1400(08)00012-1.
↑Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP.(2012).„ChEMBL: a large-scale bioactivity database for drug discovery”.Nucleic Acids Res40(Database issue): D1100-7.DOI:10.1093/nar/gkr777.PMID21948594.edit
↑Porter RH, Jaeschke G, Spooren W et al.(November 2005).„Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity”.J. Pharmacol. Exp. Ther.315(2): 711–21.DOI:10.1124/jpet.105.089839.PMID16040814.
↑Marino, MJ; Conn, PJ(2006).„Glutamate-based therapeutic approaches: Allosteric modulators of metabotropic glutamate receptors”.Current opinion in pharmacology6(1): 98–102.DOI:10.1016/j.coph.2005.09.006.PMID16368268.
↑Wållberg, A; Nilsson, K; Osterlund, K; Peterson, A; Elg, S; Raboisson, P; Bauer, U; Hammerland, LG et al.(2006).„Phenyl ureas of creatinine as mGluR5 antagonists. A structure-activity relationship study of fenobam analogues”.Bioorganic & medicinal chemistry letters16(5): 1142–5.DOI:10.1016/j.bmcl.2005.11.092.PMID16380255.
↑Ceccarelli, SM; Jaeschke, G; Buettelmann, B; Huwyler, J; Kolczewski, S; Peters, JU; Prinssen, E; Porter, R et al.(2007).„Rational design, synthesis, and structure-activity relationship of benzoxazolones: New potent mglu5 receptor antagonists based on the fenobam structure”.Bioorganic & medicinal chemistry letters17(5): 1302–6.DOI:10.1016/j.bmcl.2006.12.006.PMID17189691.
↑Jaeschke, G; Porter, R; Büttelmann, B; Ceccarelli, SM; Guba, W; Kuhn, B; Kolczewski, S; Huwyler, J et al.(2007).„Synthesis and biological evaluation of fenobam analogs as mGlu5 receptor antagonists”.Bioorganic & medicinal chemistry letters17(5): 1307–11.DOI:10.1016/j.bmcl.2006.12.033.PMID17196387.